- Home
- HSII vs CVAC Comparison
HSII vs CVAC Comparison
Compare HSII & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- CVAC
- Stock Information
- Founded
- HSII 1953
- CVAC 2000
- Country
- HSII United States
- CVAC Germany
- Employees
- HSII N/A
- CVAC N/A
- Industry
- HSII Diversified Commercial Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- CVAC Health Care
- Exchange
- HSII Nasdaq
- CVAC Nasdaq
- Market Cap
- HSII 904.3M
- CVAC 818.8M
- IPO Year
- HSII 1999
- CVAC 2020
- Fundamental
- Price
- HSII $41.41
- CVAC $3.30
- Analyst Decision
- HSII Buy
- CVAC Hold
- Analyst Count
- HSII 2
- CVAC 3
- Target Price
- HSII $46.00
- CVAC $10.00
- AVG Volume (30 Days)
- HSII 104.1K
- CVAC 656.5K
- Earning Date
- HSII 03-03-2025
- CVAC 11-12-2024
- Dividend Yield
- HSII 1.45%
- CVAC N/A
- EPS Growth
- HSII N/A
- CVAC N/A
- EPS
- HSII 1.83
- CVAC N/A
- Revenue
- HSII $1,075,544,000.00
- CVAC $70,565,734.00
- Revenue This Year
- HSII $7.90
- CVAC $742.57
- Revenue Next Year
- HSII $3.07
- CVAC N/A
- P/E Ratio
- HSII $22.67
- CVAC N/A
- Revenue Growth
- HSII 6.55
- CVAC 75.11
- 52 Week Low
- HSII $28.58
- CVAC $2.22
- 52 Week High
- HSII $49.02
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- HSII 22.70
- CVAC 39.12
- Support Level
- HSII $42.38
- CVAC $3.53
- Resistance Level
- HSII $46.52
- CVAC $3.72
- Average True Range (ATR)
- HSII 1.14
- CVAC 0.18
- MACD
- HSII -0.50
- CVAC -0.06
- Stochastic Oscillator
- HSII 5.31
- CVAC 10.96
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.